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Abstract
In cancer research, profiling studies have been extensively conducted, searching for genes/SNPs
associated with prognosis. Cancer is a heterogeneous disease. Examining similarity and differ-
ence in the genetic basis of multiple subtypes of the same cancer can lead to better understanding
of their connections and distinctions. Classic meta-analysis approaches analyze each subtype
separately and then compare analysis results across subtypes. Integrative analysis approaches,
in contrast, analyze the raw data on multiple subtypes simultaneously and can outperform meta-
analysis. In this study, prognosis data on multiple subtypes of the same cancer are analyzed.
An AFT (accelerated failure time) model is adopted to describe survival. The genetic basis of
multiple subtypes is described using the heterogeneity model, which allows a gene/SNP to be
associated with the prognosis of some subtypes but not the others. A compound penalization
approach is developed to conduct gene-level analysis and identify genes that contain impor-
tant SNPs associated with prognosis. The proposed approach has an intuitive formulation and
can be realized using an iterative algorithm. Asymptotic properties are rigorously established.
Simulation shows that the proposed approach has satisfactory performance and outperforms
meta-analysis using penalization. An NHL (non-Hodgkin lymphoma) prognosis study with
SNP measurements is analyzed. Genes associated with the three major subtypes, namely DL-
BCL, FL, and CLL/SLL, are identified. The proposed approach identifies genes different from
alternative analysis and has reasonable prediction performance.
Keywords: Cancer prognosis; Integrative analysis; Marker selection; Penalization.
1 Introduction
Profiling studies have been extensively conducted in cancer research, searching for SNPs (single
nucleotide polymorphisms) and genes that are associated with prognosis. Cancer is a heterogeneous
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disease. Different subtypes of the same cancer usually have different prognosis patterns and different
associated genes/SNPs. Consider NHL (non-Hodgkin lymphoma), which is a heterogeneous group
of malignancies ranging from very indolent forms to aggressive ones. As discussed in Zhang et al.
(2011), different subtypes of NHL are largely different. For example, DLBCL, the largest subtype,
is aggressive, whereas FL, the second largest subtype, is indolent. Chromosomal translocations
such as t(3, 22) are specific to DLBCL, whereas others such as t(14, 18) are specific to FL. On the
other hand, different subtypes may also share common susceptibility genes/SNPs. Genes in the
cell cycle, multiple signaling, RAS, and DNA repair pathways are involved in the development and
progression of multiple cancers including NHL. For NHL, Han X. et al. (2010) and Ma et al. (2010)
have found that SNPs in multiple genes, such as BRCA2, CASP3, IRF1, BCL2, NAT2, ALXO12B,
are associated with both DLBCL and FL. Investigating the similarity and difference in the genetic
basis of multiple subtypes of the same cancer can lead to better understanding of the connections
and distinctions among subtypes (Rhodes et al. 2004; Goh and Choi 2012).
A comparable setting where the discussion and proposed method are relevant is the analysis of
prognosis data on multiple types of cancers. As discussed in Rhodes et al. (2004) and followup
studies, susceptibility genes shared by multiple types of cancers are more likely to represent the
more essential features of cancer, whereas cancer type-specific genes determine the distinctions
among different cancers.
When multiple subtypes of the same cancer are of interest, as discussed in Zhang et al. (2011),
most studies analyze each subtype separately and then compare results across subtypes. For NHL,
Han et al. (2010) and Ma et al. (2010) take this approach. Such a strategy fits in the classic
meta-analysis framework. With high-dimensional measurements such as SNPs, data on individual
subtypes have the “large d, small n” characteristic, with the sample size n much smaller than the
number of SNPs d. Because of the low sample size, susceptibility genes/SNPs identified from the
analysis of each subtype may have unsatisfactory properties. Recent studies have shown that, when
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multiple datasets (multiple subtypes in this study) have overlapping susceptibility SNPs/genes,
integrative analysis can analyze raw data of multiple datasets simultaneously and generate improved
analysis results over the analysis of individual datasets and meta-analysis (Liu et al. 2012; Ma et
al. 2009; Ma et al. 2012).
With data on multiple subtypes, the goal is to identify genes associated with prognosis. For
marker identification, we adopt penalization, which has been extensively applied to the analysis
of cancer prognosis data with high-dimensional genetic measurements. Single-dataset penalization
methods, such as Lasso, SCAD, bridge, MCP and their group counterparts, cannot be directly ap-
plied to the analysis of multiple datasets. With multiple datasets, the homogeneity model assumes
that, if a functional unit (gene or SNP) is identified, it is concluded as associated with prognosis
in all datasets (Liu et al. 2012). An alternative to the homogeneity model is the heterogeneity
model, under which a gene or SNP can be associated with prognosis in some datasets but not the
others. Under the heterogeneity model, research on penalization methods has been limited (Liu et
al. 2012). Compared with the existing studies which analyze gene expression data, the present one
has additional complexity. One gene may consist of multiple SNPs, and it is important to allow
different effects for SNPs within the same gene. In addition, theoretical properties of the methods
developed in Liu et al. (2012) and others have not been established. To the best of our knowledge,
the only available method that is tailored to the type of data analyzed in this study is Ma et al.
(2012), which adopts thresholding for marker selection. The thresholding method does not have a
well-defined objective function. Thus its properties can be very difficult to establish. In addition,
it may have more tuning parameters than the penalization method. Compared with the existing
studies, another advancement of this study is the analysis of a prognosis data on NHL, which may
provide insights into the genetic basis of this deadly disease.
The integrative analysis of data on multiple subtypes of cancer can be challenging. With some
cancers, the subtype information may be only partial or even wrong. In addition, the definitions
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of subtypes are still evolving. For NHL subtypes, we refer to Zhang et al. (2011) and references
therein for relevant discussions. When there are a large number of subtypes, the set of subtypes
chosen for analysis needs to be jointly determined by the scientific question of interest, quality
of data, sample size, evidence from epidemiologic studies and other factors. We acknowledge the
importance and difficulty of these issues. In this study, we focus on the development of a new
analysis approach and refer to other publications for relevant discussions.
2 Integrative Analysis under the Heterogeneity Model
2.1 Data and model settings
Assume that there are data on M subtypes of the same cancer, and there are nm iid observations
for subtype m(= 1, . . . ,M). The total sample size is n =
∑
m n
m. For subtype m, denote Tm as
the logarithm of failure time. Denote Xmo as the length-d covariate vector (SNPs in this study).
The subscript “o” is used to discriminate the original (versus weighted) covariates. For simplicity
of notation, assume that different subtypes measure the same set of covariates. In practice, if a
covariate is not measured for a specific subtype, its corresponding regression coefficient will be set
as zero. In penalization, rescaling is used to accommodate partially matched covariate sets.
For subject i of subtype m, the AFT (accelerated failure time) model assumes that
Tmi = β
m
0 +X
m′
oi β
m + ǫmi , i = 1, . . . , n
m. (1)
where βm0 is the intercept, β
m ⊆ Rd is the regression coefficient, and ǫmi is the error term. As
Tmi is subject to right censoring, we observe (Y
m
oi , δ
m
i ,X
m
oi ), where Y
m
oi = min{Tmi , Cmi }, Cmi is the
logarithm of censoring time, and δmi = I{Tmi ≤ Cmi } is the event indicator.
Compared with alternatives such as the Cox model, the AFT model has a much simpler ob-
jective function, as demonstrated in the next section, and hence significantly lower computational
cost. Such a property is particularly desirable for high-dimensional data. In addition, it directly de-
scribes event times, and its regression coefficients may have more lucid interpretations than those
4
in alternative models. As there is a lack of model diagnostics tools for high-dimensional data,
alternative models will not be discussed.
2.2 Weighted least squares estimation
Let Fˆm be the Kaplan-Meier estimator of the distribution function Fm of Tm. Following Stute
(1996), Fˆm can be written as Fˆm(y) =
∑nm
i=1 ω
m
i 1{Y mo(i) ≤ y}, where the ωmi ’s are the jumps in the
Kaplan-Meier estimator and can be expressed as
ωm1 =
δm(1)
nm
, ωmi =
δm(i)
nm − i+ 1
i−1∏
j=1
(
nm − j
nm − j + 1
)δm
(j)
, i = 2, . . . , nm.
Y mo(1) ≤ · · · ≤ Y mo(nm) are the order statistics of Y moi ’s, and δm(1), . . . , δm(nm) are the associated event
indicators. Similarly, let Xmo(1), . . . ,X
m
o(nm) be the associated covariate vectors of the ordered Y
m
i ’s.
Consider the weighted least squares objective function
Lm(βm0 , β
m) =
1
2
nm∑
i=1
ωmi
(
Y mo(i) − βm0 −Xmo(i)′βm
)2
. (2)
Let X¯mω =
∑nm
i=1 ω
m
i X
m
o(i)/
∑nm
i=1 ω
m
i , Y¯
m
ω =
∑nm
i=1 ω
m
i Y
m
o(i)/
∑nm
i=1 ω
m
i , X
m
ω(i) = (ω
m
i )
1/2(Xmo(i) −
X¯mω ), and Y
m
ω(i) = (ω
m
i )
1/2(Y mo(i) − Y¯ mω ). Using the weighted centered values, the intercept is zero.
The weighted least squares objective function can be written as
Lm(βm) =
1
2
nm∑
i=1
(
Y mω(i) −Xmω(i)′βm
)2
. (3)
This simple form makes computation affordable even with high-dimensional data.
Assume independence between data for theM subtypes. Consider the overall objective function
L(β) =
M∑
m=1
1
nm
Lm(βm).
Here we normalize Lm by nm so that the analysis is not dominated by large subtypes. When larger
subtypes are of more interest, the unnormalized objective function may be considered.
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2.3 Heterogeneity model
As formulated in Liu et al. (2012), two different models, namely the homogeneity model and
heterogeneity model, can be applied to describe the genetic basis of multiple subtypes. Under the
homogeneity model, it is postulated that multiple subtypes share the same set of susceptibility
SNPs/genes. Considering the significantly different prognosis patterns of different subtypes, this
model may be too restricted. Under the heterogeneity model, the sets of susceptibility SNPs/genes
may differ across subtypes. The heterogeneity model includes the homogeneity model as a special
case and can be more flexible.
To more explicitly describe the data and model settings, heterogeneity model, and our analysis
strategy, consider a hypothetical cancer study with three subtypes and eight SNPs representing
four genes (Table 1). Gene 1 is associated with the prognosis of all three subtypes; Gene 2 is
associated with the first two subtypes but not the third one; Gene 3 is associated with the third
subtype only; And gene 4 is not associated with any subtype. In Table 1, we show the regression
coefficient matrix whose main characteristics reflect the essence of integrative analysis under the
heterogeneity model. Unimportant genes/SNPs not associated with prognosis have no effects and
so zero regression coefficients. With penalization approaches including the proposed one, marker
identification amounts to identifying the sparsity structure of models. For an important gene/SNP
(for example SNP 1 1), its strengths of association with multiple subtypes, which are measured
with regression coefficients, may be different for different subtypes. With SNP data, analysis can
be conducted at multiple levels, particularly including SNP-level and gene-level. In this study,
we conduct gene-level analysis, which complements SNP-level analysis. As the goal is to identify
important genes that contain prognosis-associated SNPs, within an important gene, no further
selection is conducted. Thus, SNPs within the same gene have the “all in or all out” property.
Such a strategy has been adopted in Ma et al. (2012) and is different from that for SNP-level
analysis approaches.
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3 Penalized Marker Selection
Penalization is adopted for marker selection. Under the data and model settings described in the
previous section, existing penalization approaches are not directly applicable. A new penalization
approach is described in Section 3.1. An effective computational algorithm is proposed in Section
3.2. Tuning parameter selection is discussed in Section 3.3. Some practical concerns are discussed
in Section 3.4. Asymptotic properties and proofs are established in Appendix.
3.1 Penalty function
Assume that the d SNPs belong to J genes. To accommodate the scenario with partially matched
gene sets, suppose that Mj subtypes (studies) measure gene j. Without loss of generality, assume
that gene j is measured in the first Mj subtypes. Denote djk as the number of SNPs in the jth
gene and kth subtype with coefficient vector βjk = (β
1
jk, . . . , β
djk
jk )
′, j = 1, . . . , J , k = 1, . . . ,Mj .
The subscript k is kept to accommodate partially matched SNP sets for the same genes. Then
βj = (β
′
j1, . . . , β
′
jMj
)′ is the regression coefficient for all SNPs in the jth gene across all subtypes.
Here the notations are slightly more complicated than those in Section 2 to accommodate the
“SNP-within-gene” hierarchical structure and partially matched SNP/gene sets. β = (β′1, . . . , β
′
J )
′.
Consider the penalized estimate
βˆ = argmin {L(β) + Pλn,γ(β)} .
A nonzero component of βˆ indicates an association between the corresponding gene (SNP) and
subtype’s prognosis. Consider the penalty function
Pλn,γ(β) = λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖βjk‖


γ
, (4)
where λn > 0 is a data-dependent tuning parameter, cj ∝ M1−γj is a constant accommodating
partially matched gene sets, || · || is the L2 norm, and 0 < γ < 1 is the fixed bridge parameter.
7
The above penalty has been designed to tailor the special model characteristics as described
in Table 1. In our analysis, genes are the basic functional units. The penalty is the sum of J
individual terms, with one for each gene. For a specific gene, two levels of selection need to be
conducted. The first is to determine whether it is associated with any subtype at all. This step
of selection is achieved using a bridge penalty. For a gene associated with at least one subtype,
the second level of selection is to determine which subtype(s) it is associated with. This step of
selection is achieved using a Lasso-type penalty. The composition of the bridge-type penalty and
the Lasso-type penalty can achieve the desired two-level selection. One gene may contain multiple
SNPs. The effect of gene j for subtype k is represented by the vector βjk. Here the penalty is
imposed on the L2 norm of βjk, which can be viewed as the square root of a ridge penalty. Thus,
within a selected gene, no further SNP-level selection is conducted. If a gene is selected, all SNPs
within this gene are selected.
When djk ≡ 1 (one SNP per gene), penalty (4) becomes the group bridge, which has been
developed for the analysis of a single dataset in Huang et al. (2009). This study is among the
first to apply group bridge type penalization in integrative analysis. In addition, the proposed
penalized estimation can be more complicated than that in Huang et al. (2009) by accommodating
the “SNP-within-gene” hierarchical structure. Using composite penalization for marker selection
under the heterogeneity model has been proposed in Liu et al. (2012) for diagnosis studies with
binary responses. The penalty in Liu et al. (2012) is built on the composition of MCP and
Lasso, which is computationally more expensive, and cannot accommodate the “SNP-within-gene”
structure.
3.2 Computational algorithm
For subtype m, denote Y m as the vector composed of
√
n√
nm
Y mω s, and X
m as the matrix composed
of
√
n√
nm
Xmω s. Let Y = (Y
1′, . . . , Y M ′)′ and X = diag(X1, . . . ,XM ). Denote Xj as the submatrix of
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X corresponding to βj , and its dimension is n×
∑Mj
k=1 djk. Then
L(β) =
M∑
m=1
1
2nm
nm∑
i=1
(Y mω −Xmω ′βm)2 =
1
2n
‖Y −
J∑
j=1
Xjβj‖2. (5)
The overall objective function is
1
2n
‖Y −
J∑
j=1
Xjβj‖2 + λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖βjk‖


γ
. (6)
Define
S(β, θ) =
1
2n
‖Y −
J∑
j=1
Xjβj‖2 +
J∑
j=1
θ
1−1/γ
j c
1/γ
j
Mj∑
k=1
√
djk‖βjk‖+ τn
J∑
j=1
θj , (7)
where θ = (θ1, . . . , θJ)
′, and τn is a penalty parameter.
Proposition 3.1. If λn = τ
1−γ
n γ−γ(1 − γ)γ−1, then βˆ minimizes the objective function in (6) if
and only if (βˆ, θˆ) minimizes S(β, θ) subject to θj ≥ 0 for all j.
Proof is provided in Appendix. Examining S(β, θ) suggests that optimization with respect to
β and θ can be conducted “separately”. Optimization with respect to θ has a simple analytic
solution. Optimization with respect to β has a weighted group Lasso type objective function, for
which there exist effective algorithms. Motivated by such an observation, consider the following
algorithm:
1. Denote β(0) as the initial estimate. In our limited numerical study, the choice of initial
estimate does not have much impact on the final estimate. For simplicity, all components of
β(0) are set to be 1. Set s = 0;
2. s = s+ 1. Compute
θ
(s)
j = cj
(
1− γ
γτn
)γMj∑
k=1
√
djk
∥∥∥β(s−1)jk ∥∥∥


γ
, (8)
β(s) = argminβ

 1
2n
‖Y −
J∑
j=1
Xjβj‖2 +
J∑
j=1
(θ
(s)
j )
1−1/γc1/γj
Mj∑
k=1
√
djk‖βjk‖

 , (9)
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3. Repeat Step 2 until convergence.
In numerical study, we use the L2 norm of the difference between two consecutive estimates less
than 0.001 as the convergence criterion. The proposed algorithm always converges, since at each
step, the nonnegative objective function decreases. It is noted that as the group bridge type penalty
is not convex, the algorithm may converge to a local minimizer depending on the initial value β(0).
Using the proposed initial value works well in our numerical study. The main computational task
is the computation of β(s), which is a group Lasso type estimate and can be achieved using a group
coordinate descent algorithm (Huang et al. 2012; Liu et al. 2012). Convergence of the group
coordinate descent algorithm can be derived following Tseng (2001).
3.3 Tuning parameter selection
The proposed penalty involves two tuning parameters γ and λn. In the study of bridge type
penalties (Huang et al. 2009), the value of γ is usually fixed. Theoretically speaking, different
values of γ, as long as in the interval (0, 1), lead to similar asymptotic results. In practice as
γ → 1, the bridge type penalty goes to the Lasso type penalty; On the other hand, as γ → 0, it
behaves similarly to AIC/BIC type penalties. In our numerical study, we experiment with a few
γ values, particularly including 0.5, 0.7 and 0.9. The effect of λn is similar to that with other
penalties. As λn →∞, fewer genes/SNPs are identified.
As the function L(β) has a least squares form, we propose using BIC for tuning parameter
selection. Particularly, with a fixed γ, the optimal λn minimizes
BIC(λn) = log
{
||Y −Xβˆ(λn)||2/n
}
+ log(n)df(λn)/n.
Here we use the notation βˆ(λn) to emphasize the dependence of βˆ on λn. Motivated by Yuan and
Lin (2006), an approximation of the degree of freedom is adopted as
d˜f(λn) =
J∑
j=1
Mj∑
k=1
I(||βˆjk|| > 0) +
J∑
j=1
Mj∑
k=1
||βˆjk||
||βˆLSjk ||
(djk − 1). (10)
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Here βˆLSjk is obtained by fitting an AFT model (with least squares estimation) using the jth gene
and kth subtype only.
3.4 Practical considerations
With practical data, minor allele frequencies in some loci can be low. This may cause an instability
problem in the Cholesky decomposition when some eigenvalues of the correlation matrices are
too small. In the proposed penalized selection, within-gene-SNP level selection is not of interest.
To reduce the dimensionality within genes and to tackle the colinearity problem, when there is
evidence of a lack of stability, we first conduct principal component analysis (PCA) within genes.
Specifically, we choose the number of PCs such that at least 90% of the total variation is explained.
Then the PCs, as opposed to the original SNP measurements, are used in downstream analysis.
Our empirical study suggests that this simple step may ensure that the smallest eigenvalues of the
covariance matrices are not too small and that the Cholesky decomposition is stable.
4 Simulation Study
Three datasets (subtypes) are simulated, each with 100 subjects. For each subject, the genotypes
of 200 genes are simulated, each with 5 SNPs. There are thus a total of 1000 SNPs for each
subtype. The genotypes are first generated from multivariate normal distributions. Then the value
of each SNP is set equal to 0, 1, or 2, depending on whether the continuous (normally distributed)
value is < −c, ∈ [−c, c], or > c, where c is the 3rd quartile of the standard normal distribution.
Thus on average, each SNP has equal allele frequencies. Genotype j and k, if from different genes,
have correlation coefficient 0.2|j−k|. For genotypes from the same genes, consider the following two
correlation structures. The first is the auto-regressive correlation, where genotype j and k have
correlation coefficient ρ|j−k|. ρ = 0.2, 0.5, and 0.8, corresponding to weak, moderate, and strong
correlations, respectively. The second is the banded correlation structure. Here three scenarios are
considered. Under the first scenario, genotype j and k have correlation coefficient 0.2 if |j− k| = 1,
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0.1 if |j − k| = 2, and 0 otherwise; Under the second scenario, genotype j and k have correlation
coefficient 0.5 if |j− k| = 1, 0.25 if |j− k| = 2, and 0 otherwise. Under the third scenario, genotype
j and k have correlation coefficient 0.6 if |j − k| = 1, 0.33 if |j − k| = 2, and 0 otherwise.
Consider two cases of the nonzero regression coefficients. In case 1, the nonzero regression
coefficients for subtype 1 and 2 are (0.15, 0.15, 0.15, 0.15, 0.15, 0.1, 0.1, 0.1, 0.1, 0.1, 0.15, 0.15,
0.15, 0.15, 0.15, 0.1, 0.1, 0.1, 0.1, 0.1), and the nonzero coefficients for subtype 3 are (0.1, 0.1, 0.1,
0.1, 0.1, 0.15, 0.15, 0.15, 0.15, 0.15, 0.15, 0.15, 0.15, 0.15, 0.15, 0.1, 0.1, 0.1, 0.1, 0.1). In case 2,
the nonzero regression coefficients for subtype 1 and 2 are (0.15, 0.15, 0.15, 0.15, 0, 0, 0.1, 0.1, 0.1,
0.1, 0.15, 0.15, 0.15, 0.15, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1), and the nonzero coefficients for subtype 3 are
(0.1, 0.1, 0.1, 0.1, 0.1, 0.15, 0.15, 0.15, 0.15, 0, 0.15, 0.15, 0.15, 0.15, 0, 0, 0.1, 0.1, 0.1, 0.1). Thus,
across the three subtypes, there are 60 SNPs associated with prognosis, representing 12 genes.
Two scenarios under the heterogeneity model are considered. Under the first scenario, all
three subtypes share three common susceptibility genes, and each subtype has one subtype-specific
susceptibility gene. The “unmatching rate” of susceptibility genes is thus 25%. Under the second
scenario, the three subtypes share two common susceptibility genes, and each subtype has two
subtype-specific susceptibility genes. The unmatching rate of susceptibility genes is 50%. As a
special case of the heterogeneity model, the homogeneity model is also considered, under which all
three subtypes have the same susceptibility genes.
The logarithms of event times are generated from the AFT models with intercept equal to
0.5 and normally distributed random errors. The logarithms of censoring times are generated as
uniformly distributed and independent of the event times. The censoring distribution parameters
are adjusted so that overall censoring rate is about 30%.
Beyond the proposed approach, simulated data are also analyzed using a meta-analysis ap-
proach. Here each subtype is analyzed using the group Lasso (GLasso) approach, where a “group”
corresponds to one gene with multiple SNPs. Then the identified gene lists are combined across
12
subtypes. With both approaches, the tuning parameters are chosen using BIC. With the proposed
approach, we experiment with γ =0.5, 0.7, and 0.9. Summary statistics on gene identification
accuracy based on 100 replicates are shown in Table 2-3 and 5-8 (Appendix).
Simulation suggests that performance of the proposed approach depends on the correlation
structure, values of nonzero regression coefficients, and γ value. As correlation gets stronger, in
general, more true positives and more false positives are identified. We fail to observe a clear pattern
for the dependence (of the performance of proposed approach) on nonzero regression coefficients.
As γ gets larger, also more true positives and more false positives are identified. This observation
is reasonable, considering that when γ → 1, bridge penalization becomes close to Lasso, and that
Lasso-type penalization tends to over-select. Under almost all simulated scenarios, the proposed
approach identifies more true positives than GLasso. For example in Table 2, under the AR
correlation with ρ = 0.5, GLasso identifies 6.7 true positives, whereas the proposed approach
identifies 10.7, 10.8, and 11.0 true positives under different γ values. Under all simulated scenarios,
the proposed approach identifies much fewer false positives. For example in Table 2, under the
banded correlation scenario 2, GLasso identifies 38 false positives, whereas the proposed approach
identifies 4, 4.3, and 9.8 false positives under different γ values. Observations under the homogeneity
model (Table 7 and 8) are similar. We have experimented with a few other settings and reached
similar conclusions.
5 Analysis of NHL Genetic Association Data
NHL is the fifth leading cause of cancer incidence and mortality in the US and remains poorly under-
stood and largely incurable. A genetic association study was conducted, searching for SNPs/genes
associated with overall survival in NHL patients (Zhang et al. 2005). The prognostic cohort consists
of 575 NHL patients, among whom 496 donated either blood or buccal cell samples. All cases were
classified into NHL subtypes according to the World Health Organization classification system.
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Specifically, 155 had DLBCL, 117 had FL, 57 had CLL/SLL, 34 had MZBL, 37 had T/NK-cell
lymphoma, and 96 had other subtypes. Because of sample size consideration, we focus on DLBCL,
FL, and CLL/SLL, the three largest subtypes in this dataset. The study cohort was assembled
in Connecticut between 1996 and 2000. Vital status of all subjects was abstracted from the CTR
(Connecticut Tumor Registry) in 2008.
When genotyping, we took a candidate gene approach. Specifically, a total of 1462 tag SNPs
from 210 candidate genes related to immune response were genotyped using a custom-designed
GoldenGate assay. In addition, 302 SNPs in 143 candidate genes previously genotyped by Taqman
assay were also included. There were a total of 1764 SNPs, representing 333 genes. Data pre-
processing is conducted. Subjects with more than 20% SNPs missing are removed from analysis;
Then SNPs with more than 20% missing are removed. The genotyping data were missing for the
following reasons: the amount of DNA was too low, samples failed to amplify, samples amplified
but their genotype could not be determined due to ambiguous results, or the DNA quality was
poor. The remaining missing SNP measurements are then imputed. A total of 1,633 SNPs pass
processing, representing 238 genes.
For DLBCL, 139 patients pass processing. Among them, 61 died, with survival times ranging
from 0.47 to 10.46 years (mean 4.16 years). For the 78 censored patients, the follow up times range
from 5.58 to 11.45 years (mean 9.08 years). For FL, 102 patients pass processing. Among them,
33 died, with survival times ranging from 0.91 to 10.23 years. For the 69 censored patients, the
follow up times range from 4.96 to 11.39 years, with mean 8.83 years. For CLL/SLL, 50 patients
pass processing. Among them, 27 died, with survival times ranging from 1.91 to 10.13 years (mean
4.85 years). For the 23 censored patients, the follow up times range from 4.92 to 11.07 years, with
mean 8.83 years.
Analysis results using the proposed approach are shown in Table 4 and 9-11 (Appendix). In
particular, Table 4 contains the L2 norms of the identified genes, whereas Table 9-11 contain the
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estimated regression coefficients for SNPs. Fourteen genes are identified as associated with the
overall survival of DLBCL; Twelve genes are identified as associated with FL; And five genes are
identified as associated with CLL/SLL. Among the identified genes, MBP and STAT4 are shared
by all three subtypes, ALOX5, IL10, IRAK2, LMAN1, MIF, and NCF4 are shared by two subtypes,
and thirteen other genes are identified as subtype-specific.
Among genes shared by multiple subtypes, gene ALOX5 encodes a member of the lipoxygenase
gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. Mutations
in the promoter region of this gene lead to a diminished response to antileukotriene drugs used
in the treatment of asthma and are associated with atherosclerosis and several cancers. Studies
that have identified this gene as a marker of NHL include Mahshid et al. (2009), Feltenmark
et al. (1995) and others. The protein encoded by gene IL10 is a cytokine produced primarily
by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects in
immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class
II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation,
and antibody production. This cytokine can block NF-kappa B activity, and is involved in the
regulation of the JAK-STAT signaling pathway. The involvement of IL10 in NHL has been proposed
in Bi et al. (2012) and Deng et al. (2013). IRAK2 encodes the interleukin-1 receptor-associated
kinase 2, one of two putative serine/threonine kinases that become associated with the interleukin-1
receptor (IL1R) upon stimulation. It is identified as associated with NHL in Ngo et al. (2011). The
protein encoded by gene LMAN1 is a type I integral membrane protein localized in the intermediate
region between the endoplasmic reticulum and the Golgi. The protein is a mannose-specific lectin
and a member of a novel family of plant lectin homologs in the secretory pathway of animal
cells. Mutations in the gene are associated with a coagulation defect. It has been identified as
a marker for gastric, colorectal, and prostate cancer. Myelin basic protein (MBP) is a protein
important in the process of myelination of nerves in the central nervous system (CNS). MBP plays
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an important role in demyelinating diseases such as multiple sclerosis. Its involvement in NHL has
been discussed in Hu et al. (2012) and Han et al. (2010). Gene MIF encodes a lymphokine involved
in cell-mediated immunity, immunoregulation, and inflammation. It plays a role in the regulation
of macrophage function in host defense through the suppression of anti-inflammatory effects of
glucocorticoids. This lymphokine and the JAB1 protein form a complex in the cytosol near the
peripheral plasma membrane, which may indicate an additional role in integrin signaling pathways.
Studies such as Xue et al. (2010) and Talos et al. (2005) have identified it as a marker of NHL. The
protein encoded by gene NCF4 is a cytosolic regulatory component of the superoxide-producing
phagocyte NADPH-oxidase, a multicomponent enzyme system important for host defense. It is
identified as an NHL susceptibility gene in Kim et al. (2012). The protein encoded by gene STAT4
is a member of the STAT family of transcription factors. In response to cytokines and growth
factors, STAT family members are phosphorylated by the receptor associated kinases, and then
form homo- or heterodimers that translocate to the cell nucleus where they act as transcription
activators. This protein is essential for mediating responses to IL12 in lymphocytes, and regulating
the differentiation of T helper cells. Involvement of this gene in NHL risk and progression has been
discussed in Chang et al. (2010) and Chang et al. (2009).
The relative stability of identified genes is evaluated using a random sampling approach (Huang
and Ma 2010). In particular, we randomly sample 3/4 of the subjects and apply the proposed
approach to identify prognosis-associated genes. This process is repeated 100 times. For each gene,
we compute the probability of it being identified out of the 100 samplings. This probability is
referred to as the observed occurrence index in Huang and Ma (2010) and measures the relative
stability. Table 4 shows that only gene IL10 for DLBCL has a low occurrence index (0.21). All
other observed occurrence indexes are high, suggesting relatively satisfactory stability. Prediction
performance is also evaluated using a random sampling approach. In particular, genes are identified
and models are constructed using 3/4 of randomly sampled subjects. Then prediction is made for
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the rest 1/4 subjects. Based on the predicted Xm′βˆm, subjects are separated into two risk groups.
The logrank statistic is computed to compare the survival risk of the two groups. This process is
repeated 100 times, and the mean logrank statistic is computed as 7.1 (p-value 0.0077), suggesting
satisfactory prediction.
For comparison, we also analyze each subtype separately using GLasso (results shown in Ta-
ble 12, Appendix). Twenty-six genes are identified as associated with the prognosis of DLBCL,
seventeen genes are identified as associated with FL, and eight genes are identified as associated
with CLL/SLL. Among those genes, three are shared by two subtypes. The identified genes are
different from those using the proposed approach. Computation of the observed occurrence index
shows that the identified genes also have satisfactory stability. Prediction evaluation generates a
logrank statistic of 0.2 (p-value 0.65), which is considerably smaller than that using the proposed
approach.
6 Discussion
In this study, with prognosis data on multiple subtypes of the same cancer, we develop a penal-
ization approach which can conduct integrative analysis, identify important genes that contain
SNPs associated with multiple subtypes, and allow for subtype-specific susceptibility genes. The
proposed approach can be realized using an effective iterative algorithm. Under mild conditions, it
has the much desired consistency properties. Simulation shows that the proposed approach outper-
forms penalization-based meta-analysis, with more true positives and fewer false positives. In the
analysis of NHL prognosis data, it identifies multiple genes shared by two or three subtypes as well
as subtype-specific genes. The shared genes have important biological implications. The proposed
approach also leads to significantly better prediction performance.
To avoid confusion, in our description we focus on the scenario with multiple subtypes of the
same cancer and the “SNP-within-gene” structure. The proposed approach is directly applicable to
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the analysis of multiple types of cancers and “gene-within-cluster (pathway)” and other structures.
In addition, with minor modifications, analysis of prognosis data under other models and analysis
of diagnosis data can be conducted. The proposed penalty is built on bridge-type penalties. We
conjecture that it is possible to build on other penalties such as MCP. Our limited investigation
shows that under the present setup, the proposed penalty may have the lowest computational cost.
In data analysis, our preliminary search shows that the common genes shared by multiple subtypes
have important implications. However, because of the following limitations, the analysis results
should be interpreted with caution. First, the sample size is still limited. Second, the NHL study
takes a candidate gene approach. It is possible that important genes have been missed in the
profiling stage. Third, the proposed evaluation is cross-validation based. Although it can compare
different approaches on the same ground, it does not use completely independent data. More,
independent studies are needed to fully comprehend the data analysis results.
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Table 1: Matrix of regression coefficients for a cancer study with three subtypes, four genes and
eight SNPs. An empty cell corresponds to a zero regression coefficient.
Subtype
Gene SNP S1 S2 S3
1 1 1 0.20 0.19 0.21
1 2 -0.22 -0.19 -0.21
2 2 1 0.18 0.21
2 2 -0.21 -0.21
3 3 1 0.21
3 2 -0.18
4 4 1
4 2
Table 2: Simulation under the heterogeneity model: unmatching rate=25% and nonzero regression
coefficients under case 1. In each cell, the first row is number of true positives (standard deviation),
and the second row is model size (standard deviation).
Correlation GLasso Proposed
γ = 0.5 γ = 0.7 γ = 0.9
AR ρ =0.2 5.7(2.4) 6.7(5.2) 7.4(4.6) 8.9(2.8)
36.4(16.5) 9.5(7.6) 10.7(6.6) 20.1(6.3)
AR ρ =0.5 6.7(2.4) 10.7(3.0) 10.8(2.8) 11.0(1.9)
39.7(19.3) 14.4(4.5) 14.7(4.0) 17.1(4.5)
AR ρ =0.8 9.4(2.3) 12.0(0.2) 12.0(0.2) 11.9(0.2)
50.2(19.3) 14.4(1.9) 14.6(1.9) 15.6(2.7)
Banded 1 5.3(2.6) 7.8(5.0) 8.6(4.4) 8.9(3.6)
33.8(16.2) 11.0(7.1) 11.9(5.9) 20.5(7.0)
Banded 2 7.5(2.8) 10.6(3.3) 11.2(2.2) 11.3(1.7)
45.5(21.7) 14.6(4.8) 15.5(3.7) 21.1(7.0)
Banded 3 7.9(2.4) 11.5(1.9) 11.5(1.5) 11.6(1.1)
44.2(17.7) 15.4(3.0) 15.4(2.7) 18.8(5.2)
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Table 3: Simulation under the heterogeneity model: unmatching rate=50% and nonzero regression
coefficients under case 1. In each cell, the first row is number of true positives (standard deviation),
and the second row is model size (standard deviation).
Correlation GLasso Proposed
γ = 0.5 γ = 0.7 γ = 0.9
AR ρ =0.2 4.6(2.3) 3.7(4.1) 5.8(3.8) 8.3(2.1)
30.7(16.9) 5.4(7.0) 10.3(6.9) 22.2(6.8)
AR ρ =0.5 6.5(3.0) 9.6(3.5) 9.7(3.1) 10.1(2.3)
36.1(20.1) 16.8(7.5) 17.2(6.9) 21.1(6.8)
AR ρ =0.8 9.7(2.2) 11.5(0.9) 11.5(0.7) 11.6(0.7)
54.5(17.5) 19.4(3.9) 18.4(4.1) 20.2(5.8)
Banded 1 4.7(2.4) 4.4(4.1) 5.9(3.8) 7.7(2.9)
34.5(17.6) 6.7(7.2) 10.8(7.7) 20.8(9.2)
Banded 2 7.5(2.5) 8.4(3.9) 9.1(3.1) 10.0(1.7)
47.1(19.4) 14.4(7.7) 15.9(6.1) 23.5(7.1)
Banded 3 7.3(2.4) 9.5(2.9) 9.9(2.6) 10.1(2.2)
43.2(19.6) 16.6(6.7) 17.7(5.9) 22.9(7.6)
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Table 4: Analysis of the NHL data using the proposed approach: L2-norm of estimate for a specific
gene; OOI: observed occurrence index.
Gene DLBCL FL CLL/SLL
L2-norm OOI L2-norm OOI L2-norm OOI
ALOX12 0.02 0.83
ALOX15B 0.01 0.76
ALOX5 0.02 0.71 0.01 0.64
CLCA1 0.02 0.83
CSF2 0.02 0.86
DEFB1 0.03 0.97
IL10 1.E-04 0.21 0.02 0.62
IL17C 0.02 0.78
IRAK2 0.02 0.88 0.01 0.80
LIG4 0.01 0.87
LMAN1 0.02 0.71 0.02 0.77
MBP 0.01 0.68 4.E-03 0.60 0.04 0.68
MCP 0.01 0.83
MEFV 0.02 0.85
MIF 0.02 0.83 1.E-03 0.53
MUC6 0.03 0.99
NCF4 0.01 0.64 0.01 0.64
PTK9L 0.01 0.66
SERPINB3 0.01 0.55
SOD3 4.E-03 0.47
STAT4 0.02 0.95 0.01 0.88 0.01 0.91
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7 Appendix
7.1 Statistical properties and proofs
In this section, we use the same notations as in Section 2 and 3.1. The PCA step described in
Section 3.4 is optional and mainly for practical consideration. If PCA is actually conducted, the
djk values may be smaller.
Proof of Proposition 3.1. We have minβ,θ S(β, θ) = minβ Sˆ(β),
where Sˆ(β) = minθ{S(β, θ) : θ ≥ 0}. For any β,
θˆ(β) ≡ argmin{S(β, θ) : θ ≥ 0} = argmin


J∑
j=1
θ
1−1/γ
j c
1/γ
j

Mj∑
k=1
√
djk ‖βjk‖

+ τn J∑
j=1
θj

 .
Therefore, θˆ(β) = (θˆ1(β), . . . , θˆJ(β))
′ satisfies
(1/γ − 1)θˆ−1/γj (β)c1/γj
Mj∑
k=1
√
djk ‖βjk‖ = τn, (j = 1, . . . , J).
Write Sˆ(β) = S(β, θˆ(β)), and substitute the expressions
θˆj(β) = cj
(
γ
1− γ
)1−γMj∑
k=1
√
djk ‖βjk‖


γ
, θˆ
1−1/γ
j (β) =
(
γ
1− γ
)
c
1−1/γ
j τ
1−γ
n(∑Mj
k=1
√
djk ‖βjk‖
)1−γ
into S(β, θˆ(β)). After some algebra, we obtain
Sˆ(β) =
1
2n
‖Y −Xβ‖2 + λn
J∑
j=1
cj

Mj∑
k=1
√
djk ‖βjk‖


γ
.
Then if λn = τ
1−γ
n γ−γ(1 − γ)γ−1, Sˆ(β) and the objective function defined in Section 3.1 are
equivalent.
Let B1 and B2 be the index sets of genes with nonzero and zero norms of regression coefficients,
respectively. Let β0 be the true parameter vector of β, q
m be the size of the set {j : ‖β0jm‖ 6= 0},
and q =
∑M
m=1 q
m (that is, the total number of associations between genes and prognosis across
1
all subtypes). Without loss of generality, suppose that ‖β0jk‖ 6= 0 for all j = 1, . . . , J1 and some
k = 1, . . . ,Mj . With X as the full design matrix (defined in Section 3.2), denote XB1 as the
design matrix corresponding to B1. Define Σn = n
−1X ′X, Σ1n = n−1X ′B1XB1. Further for
any index set A, let XA denote the corresponding design matrix, and ΣA = n
−1X ′AXA. Let
A1 = {(j, k) : ‖βˆ0jk‖ 6= 0}.
We make the following assumptions: (A1) M is finite. q is finite. For subtype m (= 1, . . . ,M),
{(Y moi , δmi ,Xmoi ), i = 1, . . . , nm} are iid. The errors {ǫm1 , . . . , ǫmnm} are iid with mean zero and finite
variance (σm)2. Denote ǫm = (ǫm1 , . . . , ǫ
m
nm)
′, and ǫ = (ǫ1′, . . . , ǫM ′)′. Denote σ2 = maxm(σm)2. The
ith component of ǫm, ǫmi , is subgaussian, in the sense that there exist K1,K2 > 0 such that the tail
probability satisfies P (|ǫmi | > u) ≤ K2exp(−K1u2) for all u ≥ 0. (A2) For subtype m (= 1, . . . ,M),
the errors (ǫm1 , . . . , ǫ
m
nm) are independent of the Kaplan-Meier weights (ω
m
1 , . . . , ω
m
nm). The covariates
are bounded. (A3) The design matrix satisfies the sparse Riesz condition (SRC) with rank q∗.
That is, there exist constants 0 < c∗ < c∗ < ∞, such that for q∗ = (3 + 4C)q and C = c∗/c∗, with
probability converging to 1, c∗ ≤ ν′ΣAν‖ν‖2 ≤ c∗, ∀A with |A| = q∗ and ν ∈ Rq
∗
. In addition, the SRC
condition holds for the design matrix of each subtype separately with rank qm∗ for subtypem. (A4)
λn(logd/n)
γ/2−1 →∞. Let ηn = maxj cj
(∑Mj
k=1
√
djk‖β0jk‖
)γ−1
.
∑J
j=1
∑Mj
k=1
√
djk‖β0jk‖ = O(1)
and ηn = O(1).
The above assumptions are in parallel with those in Huang and Ma (2010). Further compli-
cations are introduced to accommodate the multi-datatsets setting, heterogeneity across subtypes,
and “SNP-within-gene” structure. Main properties of the penalized estimate can be summarized
as follows.
Theorem 7.1. Suppose the (A1)–(A3) hold and λn ≥ O(1)
√
log(d)/n. Then
1. With probability converging to 1, |A1| ≤ (2 + 4C)q.
2. ‖βˆ−β0‖2 ≤ 256λnη
2
n
c2∗
+Op
( |A1|logd
nc2∗
)
. In particular, if λn = O(1)
√
log(d)/n, then ‖βˆ−β0‖2 =
2
Op (logd/n).
The above result establishes that the number of identified genes is a finite multiply of the true
number of associated genes, which is assumed to be finite in (A1). In addition, if log(d)/n → 0,
the estimate is L2 estimation consistent. The selection and estimation results can be further
strengthened as follows.
Theorem 7.2. Suppose that (A1)–(A4) hold.
1. It holds that βˆB2=0 with probability converging to 1.
2. Suppose that {B1, β0B1} are fixed unknown. In the AFT models, the subgaussian condi-
tions are strengthened to normal distributions. Σmω1nm = (n
m)−1/2(XmωBm1 )
′XmωBm1 → Σ
m
ω1
and n−1/2X ′B1ǫ =
∑M
m=1(n
m)−1/2(XmωBm1 )
′ǫm → Z ∼ N(0,∑Mm=1(σm)2Σmω1) in distribution.
Then, in distribution,
√
n(βˆB1 − β0B1)→ argmin{V1(u) : u ∈ R|B1|},
where
V1(u) = −2u′Z + u′Σ1u+ γλ0
|B1|∑
j=1
cj

Mj∑
k=1
√
djk‖β0jk‖


γ−1
Mj∑
k=1
{ujk
β0jk
‖β0jk‖I(‖β0jk 6= 0‖)
+‖ujk‖I(‖β0jk = 0)‖},
with ujk corresponding to the component of gene j and subtype k.
The above result establishes that under mild conditions, the proposed approach can consistently
identify genes that are associated with at least one subtype. This result is consistent with that
in Huang et al. (2009) for the analysis of a single dataset. In addition, when the random errors
have normal distributions, the asymptotic distribution can be rigorously established. To prove the
above theorems, we first establish the following lemma.
Let ζm = (ζm1 , . . . , ζ
m
n )
′, where ζmi = ω
m
i ǫ
m
i ≡ ωmi (Y mo(i) −Xm′o(i)βm0 ).
Lemma 7.3. Suppose that assumption (A2) and (A3) hold. Let ξmj = X
m′
j ζ
m, 1 ≤ j ≤ d, where
Xmj is the jth column of X
m. Let ξmn = max1≤j≤d|ξmj |. Then.
E(ξmn ) ≤ C1
√
log(d)
(√
2C2nmlog(d) + 4log(2d) + C2n
m
)
,
where C1 and C2 are two positive constants. In particular, when log(d)/n
m → 0,
E(ξmn ) = O(1)
√
nmlog(d).
Proof of Lemma 7.3. Let s2nmj = X
m′
j X
m
j . Conditional on X
m
j ’s, assumption (A2) and (A3) imply
that ξmj ’s are subgaussian. Let s
2
nm = max1≤j≤ds2nmj. By (A2) and the maximal inequality for
subgaussian random variables (Van der Varrt and Wellner 1996, Lemmas 2.2.1 and 2.2.2),
E
(
1≤j≤d
max |ξmj |
∣∣∣Xmj , 1 ≤ j ≤ d) ≤ C1snm√log(d),
for a constant C1 > 0. Therefore,
E
(
1≤j≤d
max |ξmj |
)
≤ C1
√
log(d)E(snm). (11)
Since
nm∑
i=1
E
(
Xm2j(i) − EXm2j(i)
)2
≤ 4C2nm, (12)
and
1≤j≤d
max
nm∑
i=1
EXm2j(i) ≤ C2nm. (13)
By Lemma 4.2 of Van der Geer (2008), (12) implies
E
(
1≤j≤d
max
∣∣∣∣∣
2∑
i=1
(Xm2j(i) − EXm2j(i))
∣∣∣∣∣
)
≤
√
2C2nmlog(d) + 4log(2d). (14)
Therefore, by (13) and the triangle inequality,
Es2nm ≤
√
2C2nmlog(d) + 4log(2d) + C2n
m.
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Now since Esnm ≤ (Es2nm)1/2, we have
Esnm ≤
(√
2C2nmlog(d) + 4log(2d) + C2n
m
)1/2
. (15)
The lemma follows from (11) and (15).
Proof of Theorem 7.1. Part (i) follows from the proof of Theorem 1 of Zhang and Huang (2008).
One difference is that here a subgaussian assumption is made, which is weaker than the normality
assumption in Zhang and Huang (2008). Since subgaussian random variables have the same tail
behaviors as normal random variables, the argument of Zhang and Huang (2008) goes through. In
addition, the SRC condition is imposed at a group level, as opposed to individual covariate level,
to accommodate the “SNP-within-gene” structure.
(ii) By the definition of βˆ,
1
2n
‖Y −Xβˆ‖2 + λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
≤ 1
2n
‖Y −Xβ0‖2 + λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖β0jk‖


γ
.
Thus
1
2n
‖Y −Xβˆ‖2 + λn
J1∑
j=1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
≤ 1
2n
‖Y −Xβ0‖2 + λn
J1∑
j=1
cj

Mj∑
k=1
√
djk‖β0jk‖


γ
.
Using ζ = Y −Xβ0, we have
1
2n
‖Y −Xβˆ‖2 − 1
2n
‖Y −Xβ0‖2 = 1
2n
‖X(βˆ − β0)‖2 − 1
n
ζ ′X(βˆ − β0). (16)
Let B = B1 ∪ A1 = {(j, k) : ‖β0jk‖ 6= 0 or ‖βˆjk‖ 6= 0}. Note that |B| ≤ q∗ with probability
converging to 1 by part (i), where q∗ is defined in (A3). Denote ηB = XB(βˆB − β0B).
5
Since bγ − aγ ≤ 2(b− a)bγ−1 for 0 ≤ a ≤ b,
λn
J1∑
j=1
cj(
Mj∑
k=1
√
djk‖β0jk‖)γ − λn
J1∑
j=1
cj(
Mj∑
k=1
√
djk‖βˆjk‖)γ
≤ 2λn
J1∑
j=1

cj(
Mj∑
k=1
√
djk‖β0jk‖)γ−1
Mj∑
k=1
√
djk|‖β0jk‖ − ‖βˆjk‖|


≤ 2λnηn
J1∑
j=1
Mj∑
k=1
√
djk|‖β0jk‖ − ‖βˆjk‖|
≤ 2λnηn‖βˆB − β0B‖. (17)
Following from (16) and (17), we have
1
2n
‖ηB‖2 − 1
n
ζ ′ηB ≤ 2λnηn‖βˆB − β0B‖. (18)
Let ζB be the projection of ζ to the span of XB , i.e., ζB = XB(X
′
BXB)
−1X ′Bζ. We have
ζ ′ηB = ζ ′XB(βˆB − β0B) =
{
(X ′BXB)
−1/2X ′Bζ
}′ {
(X ′BXB)
1/2(βˆB − β0B)
}
.
Therefore, by the Cauchy-Schwarz inequality,
|ζ ′ηB | ≤ ‖ζB‖ · ‖ηB‖ ≤ ‖ζB‖2 + 1
4
‖ηB‖. (19)
Combining (18) and (19),
1
2n
‖ηB‖2 ≤ 2
n
‖ζB‖2 + 4λnζn‖βˆB − β0B‖. (20)
By the SRC condition (A3),n−1‖ηB‖2 ≥ c∗‖βˆB − β0B‖2. Thus (20) implies
c∗
2
‖βˆB − β0B‖2 ≤ 2
n
‖ζB‖2 + 4 ∗ (4λnηn)
2
c∗
+
c∗
4
‖βˆB − β0B‖2.
It follows that
‖βˆB − β0B‖2 ≤ 8‖ζB‖
2
nc∗
+
(16λnηn)
2
c2∗
. (21)
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Now
‖ζB‖2 = ‖(X ′BXB)−1/2X ′Bζ‖2 ≤
1
nc∗
‖X ′Bζ‖2
≤ 1
nc∗ A:|A|≤q∗
max ‖X ′Aζ‖2 ≤
1
c∗ m
max
Am:|Am|≤qm∗
max
1
nm
‖Xm′ωAmζm‖2.
We have
Am:|Am|≤qm∗
max ‖Xm′ωAmζm‖2 =
Am:|Am|≤qm∗
max
∑
j∈Am
|Xm′ωj ζm|2 ≤ qm∗ 1≤j≤dmax |X
m′
ωj ζ
m|2.
By Lemma 7.3,
1≤j≤d
max |Xm′ωj ζm|2 = nm 1≤j≤dmax |(n
m)−
1
2Xm′ωj ζ
m|2 = Op(nmlogd).
Therefore,
‖ζB‖2 = Op(q∗logd). (22)
The result follows from (21) and (22).
Proof of Theorem 7.2. (i) We prove the first part of Theorem 7.2.
Define β˜ by
β˜j =
{
βˆj, (j ∈ B1)
0, (j ∈ B2)
.
The Karush-Kuhn-Tucker condition for (9) implies that
1
n
(Y −Xβˆ)′Xjl = γcjλn

Mj∑
k=1
√
djk‖βˆjk‖


γ−1√
djl
βˆjl
‖βˆjl‖
I(‖βˆjl‖ 6= 0),
where Xjl is the sub-matrix corresponding to the jth gene of the lth subtype.
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Since (βˆjl − β˜jl)′ βˆjl‖βˆjl‖ = ‖βˆjl‖I(‖β0jl‖ = 0), we have
1
n
(Y −Xβˆ)′X(βˆ − β˜) =
∑
{j:‖β0jl‖=0}∋j
γcjλn

Mj∑
k=1
√
djk‖βˆjk‖


γ−1√
djl‖βˆjl‖
=
∑
{j:‖β0jl‖=0}∋j
γcjλn

Mj∑
k=1
√
djk‖βˆjk‖


γ−1√
djl
(
‖βˆjl‖ − ‖β˜jl‖
)
= γλn
J∑
j=1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ−1
·



Mj∑
l=1
√
djl‖βˆjl‖

−

Mj∑
l=1
√
djl‖β˜jl‖



 .
Since γbγ−1(b− a) ≤ bγ − aγ for 0 ≤ a ≤ b, for j ≤ J1, we have
γλn
∑J1
j=1 cj
(∑Mj
k=1
√
djk‖βˆjk‖
)γ−1 {(∑Mj
l=1
√
djl‖βˆjl‖
)
−
(∑Mj
l=1
√
djl‖β˜jl‖
)}
≤ λn
∑J1
j=1 cj
{(∑Mj
l=1
√
djl‖βˆjl‖
)γ
−
(∑Mj
l=1
√
djl‖β˜jl‖
)γ}
.
Since
(∑Mj
l=1
√
djl‖βˆjl‖
)
= 0 for j > J1, this implies that
1
n
|(Y −Xβˆ)′X(βˆ − β˜)| ≤ λn
J1∑
j=1
cj



Mj∑
l=1
√
djl‖βˆjl‖


γ
−

Mj∑
l=1
√
djl‖β˜jl‖


γ

+γλn
J∑
j=J1+1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
. (23)
By the definition of βˆ, we have
1
2n
‖Y −Xβˆ‖2 + λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
≤ 1
2n
‖Y −Xβ˜‖2 + λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖β˜jk‖


γ
.
Since
(∑Mj
k=1
√
djk‖β˜jk‖
)
= 0 for j > J1, by (23),
1
n
|(Y −Xβˆ)′X(βˆ − β˜)| + (1− γ)λn
J∑
j=J1+1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
≤ λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
− λn
J∑
j=1
cj

Mj∑
k=1
√
djk‖β˜jk‖


γ
8
≤ 1
2n
‖Y −Xβ˜‖2 − 1
2n
‖Y −Xβˆ‖2
=
1
2n
‖X(βˆ − β˜)‖2 − 1
n
(Y −Xβˆ)′X(βˆ − β˜).
Thus, by SRC condition (A3), with n−1‖X(βˆ − β˜)‖2 ≤ c∗‖βˆ − β˜‖2, we have
(1− γ)λn
J∑
j=J1+1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
≤ 1
2n
‖X(βˆ − β˜)‖2 ≤ c
∗
2
‖βˆB2‖2 ≤
c∗
2
‖βˆ − β0‖2,
which implies, by Theorem 7.1 (ii),
(1− γ)λn
J∑
j=J1+1
cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
≤ c
∗
2
‖βˆB2‖2 ≤
c∗
2
‖βˆ − β0‖2 = Op( logd
n
). (24)
We still need to find a lower bound of
∑J
j=J1+1
cj
(∑Mj
k=1
√
djk‖βˆjk‖
)γ
. Since cj ≥ 1 by assumption,
∑
{j:‖β0jl‖=0}∋j
cj

 ∑
{k:‖β0jk‖=0}∋k
√
djk‖βˆjk‖


γ
≥

 ∑
(j,k):‖β0jk‖=0
√
djk‖βˆjk‖


γ
≥ ‖βˆB2‖γ . (25)
If ‖βˆB2‖ > 0, the combination of (24) and (25) yields
(1− γ)λnC1 ≤ c
∗
2
‖βˆB2‖2−γ ≤ Op
((
logd
n
) 2−γ
2
)
.
Since λn(logd/n)
γ/2−1 →∞ by assumption, this implies that
Pr(‖βˆB2‖ > 0) ≤ Pr
{
λn
(
logd
n
) γ
2
−1
≤ Op(1)
}
→ 0.
(ii) We now prove the second part. Let hn = n
−1/2 define
V1n(u) = Ln(β0 + hn(u
′,0′)′)− Ln(β0),
with 0 being the zero vector of dimension |B2|. By (i), the following holds with large probability:
βˆ − β0 = hn(uˆ′,0′)′, uˆ = argmin
{
V1n(u);u ∈ Rd1
}
.
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The function V1n(u),u ∈ Rd1 , can be written as
V1n(u) =
{−2hnu′X ′1ǫ+ h2nu′X ′1X1u}+ λn
J1∑
j=1
cj

Mj∑
k=1
√
djk‖βˆjk + hnujk‖


γ
−cj

Mj∑
k=1
√
djk‖βˆjk‖


γ
= T1n(u) + T2n(u).
For the first term, we have
T1n(u)→D −2u′W + u′Σ1u.
For the second term,
T2n(u)→ γλ0
J1∑
j=1
cj

Mj∑
k=1
√
djk‖β0jk‖


γ−1
Mj∑
k=1
{
ujk
β0jk
‖β0jk‖I(β0jk 6= 0) + ‖ujk‖I(β0jk = 0)
}
.
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7.2 Additional numerical results
Table 5: Simulation under the heterogeneity model: unmatching rate=25% and nonzero regression
coefficients under case 2. In each cell, the first row is number of true positives (standard deviation),
and the second row is model size (standard deviation).
Correlation GLasso Proposed
γ = 0.5 γ = 0.7 γ = 0.9
AR ρ =0.2 3.8(2.1) 2.4(4.2) 4.5(4.6) 5.4(3.4)
32.7(17.5) 3.5(6.2) 7.9(7.7) 18.0(9.9)
AR ρ =0.5 6.0(2.4) 9.4(4.1) 10.2(3.2) 10.3(2.5)
36.7(16.1) 13.3(5.9) 14.7(4.7) 20.0(7.7)
AR ρ =0.8 8.0(2.4) 11.7(0.9) 11.8(0.6) 11.7(0.8)
46.9(18.5) 15.3(2.3) 15.6(3.0) 19.4(6.2)
Banded 1 3.8(2.1) 2.9(4.5) 4.4(4.5) 5.8(3.4)
31.8(17.0) 4.3(6.6) 7.0(7.0) 18.1(9.9)
Banded 2 5.2(2.4) 9.2(4.5) 9.8(3.7) 9.5(3.0)
32.7(18.8) 13.2(6.3) 14.4(5.3) 20.8(7.7)
Banded 3 5.7(2.5) 9.4(4.1) 9.7(3.4) 10.4(2.3)
35.1(17.5) 13.0(5.6) 14.7(5.2) 22.8(8.7)
Table 6: Simulation under the heterogeneity model: unmatching rate=50% and nonzero regression
coefficients under case 2. In each cell, the first row is number of true positives (standard deviation),
and the second row is model size (standard deviation).
Correlation Lasso Proposed
γ = 0.5 γ = 0.7 γ = 0.9
AR ρ =0.2 3.7(2.0) 1.8(3.3) 3.8(3.8) 6.1(2.5)
30.3(16.9) 2.8(5.4) 7.6(7.8) 21.4(8.2)
AR ρ =0.5 5.3(2.6) 8.0(3.8) 9.4(2.7) 9.5(1.7)
33.5(20.1) 13.6(7.8) 17.4(6.3) 22.9(6.7)
AR ρ =0.8 8.2(2.3) 10.6(2.2) 10.9(1.0) 11.0(1.3)
47.8(19.2) 18.1(5.5) 18.3(3.7) 21.8(6.6)
Banded 1 3.9(2.0) 1.9(3.0) 3.4(3.6) 5.8(3.1)
31.2(18.5) 3.1(5.3) 6.3(7.0) 18.5(9.0)
Banded 2 5.1(2.4) 6.4(4.0) 8.6(3.0) 8.6(2.8)
31.6(15.6) 10.4(7.4) 15.7(6.8) 21.7(8.8)
Banded 3 5.8(2.4) 8.3(3.5) 9.0(2.7) 9.4(2.1)
36.2(18.5) 13.9(7.4) 15.6(5.4) 21.7(7.2)
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Table 7: Simulation under the homogeneity model: nonzero regression coefficients under case 1.
In each cell, the first row is number of true positives (standard deviation), and the second row is
model size (standard deviation).
Correlation GLasso Proposed
γ = 0.5 γ = 0.7 γ = 0.9
AR ρ =0.2 5.4(2.3) 9.5(4.0) 9.5(4.2) 9.1(3.8)
37.6(17.2) 9.8(3.8) 10.5(4.3) 16.9(8.1)
AR ρ =0.5 7.1(2.7) 11.6(1.9) 11.6(1.6) 11.5(1.7)
41.8(21.5) 11.8(1.4) 11.8(1.3) 15.2(4.4)
AR ρ =0.8 9.7(2.4) 11.9(0.4) 12.0(0.0) 12.0(0.0)
48.3(17.8) 12.0(0.4) 12.1(0.6) 14.0(2.1)
Banded 1 5.1(2.0) 9.9(4.1) 10.1(3.8) 9.9(3.2)
33.8(16.2) 10.2(3.9) 11.2(3.6) 17.9(6.9)
Banded 2 7.5(2.7) 12.0(0.0) 12.0(0.0) 11.6(1.1)
45.5(19.3) 12.0(0.0) 12.3(1.1) 17.1(5.5)
Banded 3 8.3(2.3) 11.8(0.9) 11.9(0.8) 11.9(0.5)
50.5(18.5) 11.8(0.9) 12.0(0.9) 15.9(3.7)
Table 8: Simulation under the homogeneity model: nonzero regression coefficients under case 2.
In each cell, the first row is number of true positives (standard deviation), and the second row is
model size (standard deviation).
Correlation GLasso Proposed
γ = 0.5 γ = 0.7 γ = 0.9
AR ρ =0.2 4.1(2.4) 6.0(5.1) 6.9(4.8) 7.9(3.6)
33.0(18.8) 6.2(5.1) 8.9(5.8) 19.9(7.7)
AR ρ =0.5 6.5(2.5) 11.2(2.3) 11.4(1.7) 11.3(1.6)
39.2(18.2) 11.6(2.1) 12.4(2.0) 18.3(6.5)
AR ρ =0.8 8.2(2.6) 11.9(0.4) 11.9(0.4) 11.9(0.6)
46.9(21.9) 12.0(0.6) 12.4(1.5) 16.4(5.8)
Banded 1 4.0(2.2) 5.3(5.3) 7.0(4.7) 7.8(3.5)
33.5(16.2) 5.5(5.3) 8.1(5.3) 19.6(7.9)
Banded 2 6.0(2.2) 10.6(3.6) 11.1(2.5) 11.2(1.8)
38.1(16.8) 10.9(3.2) 12.8(3.6) 19.1(6.2)
Banded 3 6.5(2.1) 11.4(1.9) 11.2(2.0) 11.3(2.1)
39.9(16.8) 11.7(1.3) 12.5(2.1) 19.3(5.7)
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Table 9: SNP-level estimates using the proposed approach: DLBCL.
SNP Est SNP Est SNP Est SNP Est
ALOX15B 01 0.00847 LMAN1 02 -0.00386 MCP 02 -0.00366 NCF4 42 -0.00429
ALOX15B 03 0.00238 LMAN1 04 -0.00017 MCP 04 0.01080 NCF4 43 -0.00424
ALOX15B 04 0.00397 LMAN1 05 0.00876 MCP 05 -0.00116 NCF4 44 0.00086
ALOX15B 06 0.00490 LMAN1 06 -0.00343 MCP 06 0.00242 NCF4 45 -0.00098
ALOX15B 07 0.00288 LMAN1 07 0.00562 MCP 07 0.00031 NCF4 46 -0.00055
ALOX5 01 0.00357 LMAN1 08 0.00562 MCP 08 -0.00511 NCF4 49 0.00130
ALOX5 41 0.00559 LMAN1 09 0.00645 MEFV 01 0.00544 SERPINB3 01 -0.00410
ALOX5 42 0.00033 MBP 02 -0.00334 MEFV 02 0.01260 SERPINB3 02 0.00262
ALOX5 43 -0.00611 MBP 03 0.00084 MEFV 03 -0.00468 SERPINB3 05 0.00489
ALOX5 44 0.00825 MBP 04 0.00013 MEFV 04 0.00699 SERPINB3 06 0.00177
ALOX5 45 0.00357 MBP 05 0.00058 MEFV 05 -0.00081 STAT4 08 -0.00873
ALOX5 46 -0.00093 MBP 06 -0.00052 MIF 01 0.00760 STAT4 09 0.00045
ALOX5 47 0.00428 MBP 07 0.00058 MIF 01 2 0.00760 STAT4 10 0.00004
ALOX5 48 -0.00018 MBP 08 0.00171 MIF 14 -0.00358 STAT4 11 0.00485
ALOX5 49 0.00119 MBP 09 -0.00075 MIF 15 -0.00805 STAT4 12 -0.00138
ALOX5 51 0.00556 MBP 10 -0.00100 MIF 16 -0.00861 STAT4 13 -0.00156
ALOX5 52 0.00349 MBP 12 -0.00149 MIF 18 0.00750 STAT4 14 0.00097
ALOX5 53 0.00113 MBP 13 0.00118 MIF 19 0.00431 STAT4 16 -0.00500
ALOX5 54 0.01233 MBP 14 0.00006 MIF 20 0.00473 STAT4 17 -0.00605
ALOX5 55 0.00042 MBP 15 0.00003 MIF 21 0.00865 STAT4 18 0.00191
CSF2 02 0.01655 MBP 16 0.00123 MIF 22 -0.00365 STAT4 19 -0.00114
DEFB1 01 -0.00675 MBP 17 0.00021 MIF 23 -0.00232 STAT4 21 0.00118
DEFB1 02 -0.01199 MBP 18 0.00032 MUC6 01 -0.00386 STAT4 23 -0.00751
DEFB1 03 -0.00798 MBP 19 -0.00094 MUC6 02 -0.00825 STAT4 24 0.00048
DEFB1 04 0.00948 MBP 20 -0.00028 MUC6 03 -0.00041 STAT4 25 0.00687
DEFB1 05 -0.01192 MBP 21 -0.00084 MUC6 04 -0.00145 STAT4 29 0.00242
DEFB1 06 -0.00488 MBP 22 -0.00023 MUC6 07 -0.00329 STAT4 30 0.00274
DEFB1 07 -0.00561 MBP 23 -0.00159 MUC6 08 -0.00569 STAT4 31 -0.00531
DEFB1 08 -0.00195 MBP 24 -0.00097 MUC6 09 -0.00362 STAT4 33 -0.00654
DEFB1 09 0.00809 MBP 25 0.00063 MUC6 10 -0.01415 STAT4 34 0.00814
DEFB1 11 -0.00332 MBP 26 0.00116 MUC6 13 0.01833 STAT4 35 0.00020
DEFB1 12 -0.00140 MBP 27 -0.00045 MUC6 14 -0.01229 STAT4 36 0.00369
DEFB1 13 -0.01077 MBP 28 0.00022 NCF4 12 -0.00118 STAT4 37 0.00462
IL10 01 -0.00009 MBP 29 -0.00214 NCF4 18 -0.00292 STAT4 38 0.00229
IL10 02 -0.00009 MBP 30 0.00030 NCF4 33 -0.00254 STAT4 39 -0.00357
IL10 03 0.00000 MBP 31 -0.00031 NCF4 34 -0.00077 STAT4 41 0.00203
IL10 06 0.00001 MBP 32 -0.00140 NCF4 35 -0.00932 STAT4 42 0.00206
IL10 07 0.00001 MBP 33 -0.00060 NCF4 36 -0.00220 STAT4 43 0.00346
IL10 17 0.00000 MBP 34 -0.00040 NCF4 37 -0.00483 STAT4 44 0.00711
IL10 17 2 0.00000 MBP 35 0.00255 NCF4 38 -0.00229 STAT4 45 0.00061
LMAN1 01 0.00918 MBP 36 -0.00051 NCF4 39 0.00575 STAT4 46 0.00687
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Table 10: SNP-level estimates using the proposed approach: FL.
SNP Est SNP Est SNP Est SNP Est
ALOX12 06 0.01078 IRAK2 20 0.00404 MBP 23 0.00021 NCF4 46 0.00449
ALOX12 07 0.01315 IRAK2 21 0.00257 MBP 24 -0.00002 NCF4 49 0.00383
ALOX12 09 0.00692 IRAK2 22 0.00315 MBP 25 0.00075 PTK9L 01 0.00275
CLCA1 01 -0.00360 IRAK2 23 0.00319 MBP 26 -0.00051 PTK9L 02 0.01068
CLCA1 02 0.00514 IRAK2 24 -0.00416 MBP 27 -0.00013 PTK9L 03 0.00498
CLCA1 03 -0.00255 IRAK2 25 -0.00099 MBP 28 0.00049 SOD3 27 0.00399
CLCA1 04 -0.00307 IRAK2 26 -0.00563 MBP 29 -0.00156 STAT4 08 -0.00143
CLCA1 05 0.00312 IRAK2 27 0.00227 MBP 30 0.00080 STAT4 09 0.00123
CLCA1 06 -0.00192 IRAK2 28 0.00690 MBP 31 -0.00148 STAT4 10 0.00068
CLCA1 07 0.00004 LIG4 02 -0.01321 MBP 32 0.00037 STAT4 11 -0.00025
CLCA1 08 0.00606 LMAN1 01 -0.00644 MBP 33 -0.00061 STAT4 12 0.00048
CLCA1 09 -0.00514 LMAN1 02 0.00382 MBP 34 -0.00097 STAT4 13 0.00096
CLCA1 10 0.00190 LMAN1 04 -0.00467 MBP 35 -0.00030 STAT4 14 0.00050
CLCA1 11 -0.00208 LMAN1 05 0.00560 MBP 36 0.00067 STAT4 16 0.00027
CLCA1 12 0.00447 LMAN1 06 0.00355 MIF 01 -0.00031 STAT4 17 -0.00088
CLCA1 13 0.00266 LMAN1 07 -0.01116 MIF 01 2 -0.00031 STAT4 18 0.00121
CLCA1 15 -0.00221 LMAN1 08 -0.01116 MIF 14 0.00018 STAT4 19 0.00057
CLCA1 16 0.00426 LMAN1 09 -0.00280 MIF 15 0.00047 STAT4 21 0.00074
CLCA1 17 -0.00246 MBP 02 0.00000 MIF 16 0.00045 STAT4 23 -0.00026
CLCA1 18 -0.00427 MBP 03 0.00016 MIF 18 -0.00030 STAT4 24 0.00117
CLCA1 19 -0.00243 MBP 04 0.00065 MIF 19 0.00009 STAT4 25 -0.00119
CLCA1 20 0.00698 MBP 05 0.00047 MIF 20 0.00015 STAT4 29 0.00201
CLCA1 21 0.00241 MBP 06 -0.00001 MIF 21 -0.00031 STAT4 30 -0.00002
CLCA1 22 0.00865 MBP 07 0.00016 MIF 22 -0.00049 STAT4 31 -0.00118
CLCA1 23 -0.00595 MBP 08 0.00008 MIF 23 0.00021 STAT4 33 -0.00121
IL17C 01 0.01724 MBP 09 0.00124 NCF4 12 -0.00300 STAT4 34 -0.00174
IRAK2 01 -0.00111 MBP 10 0.00053 NCF4 18 0.00226 STAT4 35 0.00183
IRAK2 02 -0.00289 MBP 12 -0.00062 NCF4 33 -0.00048 STAT4 36 0.00046
IRAK2 10 0.00704 MBP 13 0.00084 NCF4 34 -0.00323 STAT4 37 -0.00041
IRAK2 11 0.00483 MBP 14 -0.00016 NCF4 35 -0.00107 STAT4 38 0.00059
IRAK2 12 -0.00195 MBP 15 -0.00066 NCF4 36 -0.00582 STAT4 39 0.00205
IRAK2 13 -0.00178 MBP 16 0.00070 NCF4 37 0.00349 STAT4 41 0.00105
IRAK2 14 -0.00234 MBP 17 0.00017 NCF4 38 -0.00065 STAT4 42 0.00011
IRAK2 15 0.00474 MBP 18 -0.00010 NCF4 39 0.00466 STAT4 43 0.00055
IRAK2 16 -0.00089 MBP 19 -0.00121 NCF4 42 0.00165 STAT4 44 0.00148
IRAK2 17 -0.00261 MBP 20 0.00020 NCF4 43 0.00013 STAT4 45 0.00062
IRAK2 18 -0.00047 MBP 21 0.00101 NCF4 44 -0.00265 STAT4 46 -0.00135
IRAK2 19 -0.00278 MBP 22 -0.00004 NCF4 45 -0.00420
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Table 11: SNP-level estimates using the proposed approach: CLL/SLL.
SNP Est SNP Est SNP Est SNP Est
ALOX5 01 0.00540 IRAK2 13 -0.00296 MBP 14 -0.00157 STAT4 12 -0.00348
ALOX5 41 -0.00105 IRAK2 14 -0.00353 MBP 15 -0.01136 STAT4 13 -0.00234
ALOX5 42 0.00280 IRAK2 15 0.00202 MBP 16 -0.00984 STAT4 14 -0.00177
ALOX5 43 0.00393 IRAK2 16 -0.00217 MBP 17 0.00380 STAT4 16 0.00067
ALOX5 44 0.00407 IRAK2 17 0.00271 MBP 18 -0.01136 STAT4 17 -0.00307
ALOX5 45 0.00504 IRAK2 18 0.00186 MBP 19 -0.00883 STAT4 18 -0.00050
ALOX5 46 -0.00096 IRAK2 19 0.00266 MBP 20 -0.00373 STAT4 19 -0.00249
ALOX5 47 0.00234 IRAK2 20 -0.00165 MBP 21 0.00081 STAT4 21 -0.00214
ALOX5 48 0.00200 IRAK2 21 -0.00307 MBP 22 -0.00438 STAT4 23 -0.00306
ALOX5 49 0.00334 IRAK2 22 -0.00025 MBP 23 0.00720 STAT4 24 -0.00144
ALOX5 51 -0.00205 IRAK2 23 0.00186 MBP 24 0.00087 STAT4 25 0.00143
ALOX5 52 -0.00043 IRAK2 24 0.00226 MBP 25 -0.00234 STAT4 29 -0.00179
ALOX5 53 0.00556 IRAK2 25 -0.00147 MBP 26 0.00109 STAT4 30 -0.00187
ALOX5 54 0.00552 IRAK2 26 -0.00364 MBP 27 0.00462 STAT4 31 -0.00045
ALOX5 55 -0.00058 IRAK2 27 0.00008 MBP 28 0.00801 STAT4 33 -0.00056
IL10 01 -0.00305 IRAK2 28 -0.00263 MBP 29 -0.00328 STAT4 34 -0.00119
IL10 02 -0.00421 MBP 02 0.00696 MBP 30 0.00278 STAT4 35 0.00023
IL10 03 -0.00313 MBP 03 0.01177 MBP 31 -0.00510 STAT4 36 -0.00246
IL10 06 -0.00212 MBP 04 0.01112 MBP 32 0.00658 STAT4 37 0.00073
IL10 07 -0.00313 MBP 05 0.00279 MBP 33 -0.00924 STAT4 38 -0.00174
IL10 17 -0.01264 MBP 06 0.01161 MBP 34 0.00411 STAT4 39 -0.00032
IL10 17 2 -0.01264 MBP 07 -0.00203 MBP 35 0.00028 STAT4 41 -0.00224
IRAK2 01 0.00421 MBP 08 -0.00272 MBP 36 0.00618 STAT4 42 -0.00210
IRAK2 02 0.00072 MBP 09 0.00394 STAT4 08 -0.00153 STAT4 43 -0.00111
IRAK2 10 -0.00098 MBP 10 -0.00098 STAT4 09 -0.00124 STAT4 44 -0.00281
IRAK2 11 -0.00096 MBP 12 0.00964 STAT4 10 -0.00123 STAT4 45 0.00067
IRAK2 12 0.00107 MBP 13 0.00312 STAT4 11 -0.00205 STAT4 46 0.00143
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Table 12: Analysis of the NHL data using group Lasso for each subtype sep-
arately: L2-norm of estimate for a specific gene; OOI: observed occurrence
index.
Gene DLBCL FL CLL/SLL
L2-norm OOI L2-norm OOI L2-norm OOI
AHR 0.017 0.97
ALOX12 0.019 1.00
ALOX15B 0.012 1.00
APEX1 0.000 0.33
BAT5 0.003 0.33
BHMT 0.003 0.74 0.001 0.28
C1QA 0.010 0.91
C1QB 0.019 0.90
C1QG 0.003 0.46
C1S 0.004 0.56
C2 0.014 0.90
C4BPA 0.001 0.25
C5 0.010 0.93
C8A 3E-04 0.36
CASP10 0.010 0.97
CCL13 0.004 0.84
CCND1 0.003 0.46
CCR1 0.008 0.79
CCR8 0.018 0.76
CENTA1 0.008 0.66
CSF2 0.006 0.88 0.006 0.69
CSF3 0.011 0.94
CTNNB1 0.004 0.54
CX3CR1 0.006 0.81
CYP1A2 0.002 0.51
CYP1B1 0.012 0.91 0.001 0.23
CYP2C9 0.017 0.90
DEF6 0.006 0.69
DEFB1 0.002 0.70
DHX33 0.015 1.00
EPHX1 0.007 0.88 0.006 0.67
ERCC2 0.010 0.97
ERCC5 0.003 0.18
GGH 0.001 0.31 0.003 0.45
ICAM2 0.009 0.90
ICAM4 0.004 0.86
ICAM5 0.011 0.95
IFNGR1 0.002 0.38
IL10 0.002 0.61 0.011 0.86
IL10RA 0.005 0.84
IL15 0.007 0.96 0.005 0.90
IL15RA 0.002 0.54
IL17C 0.013 0.92
IL3 0.004 0.84
KLK6 0.006 0.38
LEPR 0.007 0.90
LIG4 0.000 0.17
LMAN1 0.002 0.41
LPO 0.005 0.61
MASP2 0.004 0.62
MCP 0.011 0.90
MEFV 4E-04 0.38
MIF 0.002 0.43
Continued on next page
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Table 12 – continued from previous page
Gene DLBCL FL CLL/SLL
L2 norm OOI L2 norm OOI L2 norm OOI
MLH1 0.001 0.54
MTHFD2 0.004 0.52
MTR 0.001 0.28
MTRR 0.014 1.00
MUC6 0.008 0.96
MUC7 0.005 0.77
MYC 0.006 0.86
T2 0.001 0.34
NBS1 0.001 0.65
NCF4 0.001 0.18
NFKBIE 0.007 0.94 0.003 0.41
NOS3 0.006 0.84
OGG1 0.003 0.64 0.010 0.72
PDCD10 0.001 0.52
PFKFB2 0.005 0.87
PPARG 0.005 0.38
PRO1580 0.005 0.55
PTK9 0.011 1.00
PTK9L 0.018 0.92
RAD23B 0.019 1.00
RAG1 0.004 0.74
SECTM1 0.001 0.54
SELE 0.002 0.75 0.001 0.45
SENP3 0.004 0.75
SERPINB3 0.004 0.84 0.003 0.26
SOCS4 0.009 0.93
SOD3 3E-04 0.28 0.008 0.85
STAT5B 0.002 0.52
STAT6 0.002 0.57
STK11 0.002 0.48
TCN1 0.008 0.94
TICAM1 0.001 0.59
TLR1 0.019 0.90
TLR9 0.002 0.42
TNFRSF18 0.003 0.67
TOLLIP 8E-05 0.29 0.005 0.54
TP53 0.001 0.46
TYK2 0.003 0.81
WDHD1 0.015 1.00
WRN 0.003 0.49
XRCC1 0.004 0.70 9E-05 0.28
XRCC3 4E-04 0.39
XRCC4 0.010 0.76
ZNF76 0.006 0.66
ZP1 0.006 0.76
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